|  |  |
| --- | --- |
|  | Health-trilingual-high-res |

**CONSULTATION ON PROPOSED AMENDMENTS TO THE PHARMACEUTICAL SERVICES REGULATIONS (NI) 1997**

The Department of Health is conducting a 10 day targeted consultation on proposed amendments to the Pharmaceutical Services Regulations (NI) 1997, as part of the response to the current pandemic emergency. The proposals, however, will also apply to any future pandemics. A copy of the draft amending Regulations is included in this document.

The Pharmaceutical Regulations set out the legislative framework for the delivery of community pharmaceutical services in Northern Ireland, including the terms of service for chemists. The proposed amendments mainly relate to the terms of service and are detailed below and specifically relate in a period where a disease being or in anticipation of a disease being imminently pandemic and a serious risk or potentially a serious risk to human health, such as Covid-19.

Medicine Home Delivery Service

It is proposed that, in order to deal with the current pandemic, and any other pandemics that may follow,each pharmaceutical contractor must ensure that a home delivery option is in place for delivery of prescription items to eligible patients. Home delivery would support the current shielding strategy that has been put in place to limit the spread of Covid-19. It would require adhering to the following hierarchy:

* using the home delivery option that the eligible patient themselves has put in place (for example, a relative, neighbour, or volunteer collecting the prescription);
* the pharmacy delivering the items itself;
* the pharmacy finding another pharmacy who will deliver it, the first pharmacy having dispensed it; or
* the pharmacy sending the prescription form to another pharmacy, that does arrange deliveries, for them to dispense and deliver the item.

Varying core and supplementary opening hours for community pharmacies

It is further proposed as part of the current pandemic response but potentially available in the event of any pandemic, that the Health and Social Care Board (HSCB), with the agreement the Department, would be able to vary core and supplementary opening hours for community pharmacies that have statutory terms of service, for a period specified in an announcement.

This would enable the HSCB to arrange, for example, for a pharmacy to close for a certain amount of time to the public so that it could focus on dispensing, and potentially another pharmacy to be open for longer to deal with the reduced capacity in the locality. This new power to [require a pharmacy to open in an emergency](https://psnc.org.uk/wp-content/uploads/2020/04/Emergency-legislation-%E2%80%93-opening-hours.pdf) is a realistic option if a contractor is intending to close a pharmacy where the HSCB considers it essential for patients and the public, and is maintaining other pharmacies in the wider area.

Other amendments

Other proposed amendments to the Pharmaceutical Regulations mainly support the changes detailed above. Where the HSCB has made an announcement to the effect that specified terms of service of chemists are suspended in specified circumstances for a limited period, it is proposed that during that limited period the suspended terms will not form part of the arrangements to provide pharmaceutical services which chemists have with the HSCB. Similarly, if the HSCB has made an announcement to the effect that a specified term of service need not be complied with in specified circumstances for a limited period, enforcement action cannot be taken against chemists in relation to noncompliance with that term in that period. There are also ancillary provisions dealing with amendment and withdrawal of advice and announcements.

**Implementation and Guidance**

The HSCB commissions pharmaceutical services in Northern Ireland and will be responsible for implementing the new provisions. If any of the provisions are deemed appropriate, the HSCB will be responsible for producing guidance and ensuring contractors and GPs are aware of the amendments and are signposted to the guidance.

**Consultation**

Given the current emergency situation, the consultation period needs to be reduced to ensure there is no delay in making the Regulations. The targeted consultation will be for ten working days. Consultation is being carried out with key stakeholders: Health and Social Care Board, Pharmaceutical Society of Northern Ireland, Community Pharmacy NI, Pharmacy Forum NI, Ulster Chemists’ Association, National Pharmacy Association, Pharmacists’ Defence Association, British Medical Association, Royal College of General Practitioners and the Patient and Client Council.

**Equality and Human Rights considerations**

In accordance with guidance produced by the Equality Commission for Northern Ireland and in keeping with section 75 of the Northern Ireland Act 1998, any proposals have been equality screened and a preliminary decision has been taken that a full EQIA is not required. This preliminary decision is subject to change following analysis of feedback received during this consultation.

The Department has also considered the policy from a Human Rights perspective and has provisionally concluded that this policy will not engage any of the rights.

**Rural Impact**

The Rural Needs Act (Northern Ireland) 2016 places a duty on public authorities, including government departments, to have due regard to rural needs when developing, adopting, implementing or revising policies, strategies and plans and when designing and delivering public services. The proposed changes have been subject to an initial screening and it is not expected that implementation of this policy will present any specific or differential rural impacts. This preliminary decision is subject to change following analysis of feedback received during this consultation.

**Regulatory Impact**

The Department has conducted an initial screening and considers that a regulatory impact assessment is not appropriate. The proposed amendments impose no costs on charities, social economy enterprises or the voluntary sector. The proposals may ultimately have an impact on retail pharmacy businesses, however these are enabling amendments to the existing legislation at this stage. Furthermore, if the circumstances so permit, before any of these powers would be used consideration would be given to the financial implications.

**Freedom of Information**

Please see the attached Appendix to the consultation response document concerning the confidentiality of responses to consultations.

**Responding to this consultation**

A consultation response document is provided below.

Responses can be sent by email to: Karen.Simpson@health-ni.gov.uk

**The deadline for consultation responses is 5.00pm Wednesday 20th May 2020.**

**RESPONSE FORM**

**CONSULTATION ON PROPOSED AMENDMENTS TO THE PHARMACEUTICAL SERVICES REGULATIONS (NI) 1997**

Please indicate your answer to the questions by placing an **X** by your selection. You can also provide further comments in the free text field.

Please send responses electronically to Karen Simpson using the response sheet below and email address below.

**Responses to be sent by e-mail to:**

karen.simpson@health-ni.gov.uk

**The deadline for consultation responses is 5.00pm Wednesday 20th May 2020.**

**Respondent details**

I am responding: as an individual

 on behalf of an organisation

|  |  |
| --- | --- |
| **Name:** |  |
| **Job Title:** |  |
| **Organisation:** |  |
| **Address:** |  |
|  |  |
| **Tel:** |  |
|  |  |
| **e-mail:** |  |

**Part A**

**Consultation questions**

**Q1. Given the current emergency situation, do you agree with the Department’s proposal to amend the Pharmaceutical Services Regulations (NI) 1997 to provide for the options that each pharmaceutical contractor must have a home delivery option in place for delivery of prescription items to eligible patients? Medicine home delivery will ensure community pharmacy contractors can further support any shielding strategy used to limit the spread of Covid-19.**

Yes  No  Don’t know / no views 

|  |
| --- |
| **Further comments** |

**Q2. Given the current pandemic response, and the need to respond to any future pandemics, do you agree with the Department’s proposal to amend the Pharmaceutical Services Regulations (NI) 1997 to permit the Health and Social Care Board (HSCB) with the agreement of the Department, to be able to vary core and supplementary opening hours for community pharmacies that have statutory terms of services, for a period specified in an announcement?**

Yes  No  Don’t know / no views 

|  |
| --- |
| **Further comments** |

**Q3. Do you agree with the other proposed amendments to the Pharmaceutical Services Regulations (NI) 1997, as described in the correspondence above in relation to the terms of service for chemists.**

Yes  No  Don’t know / no views 

|  |
| --- |
| **Further comments** |

**General comments**

|  |
| --- |
| **Any additional general comments** |

**Part B**

**Equality Implications**

Section 75 of the Northern Ireland Act 1998 requires the Department to “have due regard” to the need to promote equality of opportunity between persons of different religious belief, political opinion, racial group, age, marital status or sexual orientation; between men and women generally; between persons with a disability and persons without; and between persons with dependants and persons without.  The Department is also required to “have regard” to the desirability of promoting good relations between persons of a different religious belief, political opinion or racial group.

The Department has also embarked on an equality screening exercise to determine if any of these recommendations are likely to have a differential impact on equality of opportunity for any of the section 75 groups. We invite you to consider the recommendations from a section 75 perspective by considering and answering the questions below. Answering these questions will contribute to the completion of the Department's Screening template and the screening outcome.

**Q1. Are the actions/proposals set out in this consultation document likely to have an adverse impact on any of the nine equality groups identified under section 75 of the Northern Ireland Act 1998?   If yes, please state the group or groups and provide comment on how these adverse impacts could be reduced or alleviated in the proposals.**

Yes  No  Don’t know / no views 

|  |
| --- |
| Comments: |

**Q2. Are you aware of any indication or evidence – qualitative or quantitative – that the actions/proposals set out in this consultation document may have an adverse impact on equality of opportunity or on good relations?  If yes, please give details and comment on what you think should be added or removed to alleviate the adverse impact.**

Yes  No  Don’t know / no views 

|  |
| --- |
| Comments: |

**Q3. Is there an opportunity to better promote equality of opportunity or good relations? If yes, please give details as to how.**

Yes  No  Don’t know / no views 

|  |
| --- |
| Comments: |

**Q4.** **Are there any aspects of these recommendations where potential human rights violations may occur?**

Yes  No  Don’t know / no views 

|  |
| --- |
| Comments: |

**Part C**

**Rural Impact**

The Rural Needs Act (NI) 2016 became operational on the 1 June 2017 and places a duty on public authorities, including government departments, to have due regard to rural needs when developing, adopting, implementing or revising policies, strategies and plans and when designing and delivering public services.

**Q1. Are the actions/proposals set out in this consultation document likely to have an adverse impact on rural areas? If yes, please provide comment on how these adverse impacts could be reduced or alleviated.**

Yes  No  Don’t know / no views 

|  |
| --- |
| Comments: |

**APPENDIX**

**Freedom of Information Act 2000 – Confidentiality of Consultations**

The Department will publish a summary of responses following completion of the consultation process. Your response, and all other responses to the consultation, may be disclosed on request. The Department can only refuse to disclose information in exceptional circumstances. Before you submit your response, please read the paragraphs below on the confidentiality of consultations and they will give you guidance on the legal position about any information given by you in response to this consultation.

**The Freedom of Information Act gives the public a right of access to any information held by a public authority, namely, the Department in this case. This right of access to information includes information provided in response to a consultation. The Department cannot automatically consider as confidential information supplied to it in response to a consultation. However, it does have the responsibility to decide whether any information provided by you in response to this consultation, including information about your identity should be made public or be treated as confidential. If you do not wish information about your identity to be made public please include an explanation in your response.**

This means that information provided by you in response to the consultation is unlikely to be treated as confidential, except in very particular circumstances. The Secretary of State for Constitutional Affairs’ Code of Practice on the Freedom of Information Act provides that:

* the Department should only accept information from third parties in confidence if it is necessary to obtain that information in connection with the exercise of any of the Department’s functions and it would not otherwise be provided;
* the Department should not agree to hold information received from third parties “in confidence” which is not confidential in nature;
* acceptance by the Department of confidentiality provisions must be for good reasons, capable of being justified to the Information Commissioner.

For further information about confidentiality of responses please contact the Information Commissioner’s Office or see web site at: <https://ico.org.uk>

Statutory Rules of Northern Ireland

2020 No.

health and personal social services

The Pharmaceutical Services (Amendments Relating to the Provision of Pharmaceutical Services During a Pandemic etc.) Regulations (Northern Ireland) 2020

Made - - - - xx May 2020

Coming into operation - xx May 2020

The Department of Health([[1]](#footnote-1)), in conjunction with the Department of Finance([[2]](#footnote-2)), makes the following Regulations in exercise of the powers conferred by Articles 63(1) and (2), 64,106(b) and 107(6) of the Health and Personal Social Services (Northern Ireland) Order 1972([[3]](#footnote-3)).

In accordance with Article 63(3) of that Order, the Department of Health has consulted with such organisations as appear to it to be representative of the pharmaceutical profession.

Citation, commencement and interpretation

1. — These Regulations may be cited as the Pharmaceutical Services (Amendments Relating to the Provision of Pharmaceutical Services During a Pandemic etc.) Regulations (Northern Ireland) 2020 and shall come into operation on xx May 2020.
	1. In these Regulations “the Pharmaceutical Regulations” means the Pharmaceutical Services Regulations (Northern Ireland) 1997([[4]](#footnote-4)).

Amendment of regulation 2 of the Pharmaceutical Regulations

1. — Regulation 2 (interpretation) is amended as follows.
	1. In paragraph (1), after the definition of “the GMS regulations” insert—

”health service” means the general health services provided for in Part VI of the Health and Personal Social Services (Northern Ireland) Order 1972([[5]](#footnote-5));

* 1. After paragraph (5) insert—

(6) In these Regulations, where reference is made to an announcement or advice of the Board that relates to a disease being, or in anticipation of a disease being imminently—

(a) pandemic; and

(b) a serious risk or potentially serious risk to human health,

it is to that announcement or advice, which may be withdrawn at any time, as amended from time to time..

Amendment of regulation 3 of the Pharmaceutical Regulations

1. In regulation 3([[6]](#footnote-6)) (pharmaceutical services), after paragraph (3) insert—

(4) A term of service of a chemist that would otherwise be part of the arrangements mentioned in paragraphs (1), (2) and (3) is temporarily not part of those arrangements, in the particular circumstances mentioned in sub-paragraph (c)(ii) and during the period mentioned in sub-paragraph (c)(iii), in the following circumstances—

(a) as a consequence of a disease being, or in anticipation of a disease being imminently—

 (i) pandemic, and

 (ii) a serious risk or potentially a serious risk to human health,

the Board with the agreement of the Department has made an announcement in respect of the prioritisation of services to be provided in, or in any part of, Northern Ireland as part of the health service;

(b) the prioritisation is in order to assist in the management of the serious risk or potentially serious risk to human health;

(c) as part of the announcement, the Board with the agreement of the Department has issued advice to the effect that chemists are not to comply with a specified term of service—

 (i) in the area to which the announcement relates,

 (ii) in the circumstances specified in the announcement, and

 (iii) during the period specified in the announcement; and

(d) the chemist is situated in the area to which the announcement relates and compliance with the term of service (it being the specified term of service) would, but for the effect of this paragraph, be a requirement of the chemist’s term of service..

New regulation 16A of the Pharmaceutical Regulations

1. After regulation 16 (claims and overpayments), insert—

Instigating disciplinary procedures under the Disciplinary Procedures Regulations in respect of a breach of term of service while a disease is or in anticipation of a disease being imminently pandemic etc.

**16A.** The Board must not instigate disciplinary procedures under the Disciplinary Procedures Regulations in respect of a breach of a term of service by a chemist in the following circumstances—

(a) as a consequence of a disease being, or in anticipation of a disease being imminently—

 (i) pandemic, and

 (ii) a serious risk or potentially a serious risk to human health,

the Board with the agreement of the Department has made an announcement in respect of the prioritisation of services to be provided in, or in any part of, Northern Ireland as part of the health service;

(b) the prioritisation is in order to assist in the management of the serious risk or potentially serious risk to human health;

(c) as part of the announcement, the Board with the agreement of the Department has issued advice to the effect that chemists need not comply with a specified term of service—

 (i) in the area to which the announcement relates,

 (ii) in the circumstances specified in the announcement, and

 (iii) during the period specified in the announcement; and

(d) the chemist—

 (i) is situated in the area to which the announcement relates, and

 (ii) has not complied with the term of service (it being the specified term of service) in the particular circumstances mentioned in sub-paragraph (c)(ii) and during the period mentioned in sub-paragraph (c)(iii)..

Amendment of Schedule 2 to the Pharmaceutical Regulations

1. — Schedule 2 is amended as follows.
	1. After paragraph 4A([[7]](#footnote-7)) (temporary opening hours and closures during an emergency requiring the flexible provision of pharmaceutical services) insert—

Pharmacy opening hours: arrangements while a disease is or in anticipation of a disease being imminently pandemic etc.

**4B.**—(1) Notwithstanding the foregoing provisions of this Part, the core or supplementary opening hours of a pharmacist (P) may be changed by the Board where, as a consequence of a disease being, or in anticipation of a disease being imminently—

(a) pandemic; and

(b) a serious risk or potentially a serious risk to human health,

the Board with the agreement of the Department has made an announcement to the effect that, in order to assist in the management of the serious risk or potentially serious risk to human health, the Board may, in the area to which the announcement relates and in the circumstances specified in the announcement, notify pharmacists of changes to core and supplementary opening hours for the period specified in the announcement.

(2) Where paragraph (1) applies, where the Board notifies P of changes to P’s core or supplementary hours at Ps pharmacy premises, those are P’s core and supplementary opening hours for the period that the Board specifies in the notification (unless the Board notifies P of further changes to P’s opening hours)..

* 1. After paragraph 5B([[8]](#footnote-8)) insert—

Home delivery service while a disease is or in anticipation of a disease being imminently pandemic etc.

**5C.**—(1) Before dispensing any item on a prescription form or supplying it in accordance with a serious shortage protocol, a pharmacist (P) must provide a home delivery option to eligible patients in respect of the item where, as a consequence of a disease being or in anticipation of a disease being imminently—

(a) pandemic; and

(b) a serious risk or potentially a serious risk to human health,

the Board with the agreement of the Department has made an announcement to the effect that, in order to assist in the management of the serious risk or potentially serious risk to human health, eligible patients are advised to stay away from pharmacy premises in the area specified, in the circumstances specified and for the duration of the period specified in the announcement.

(2) If P’s pharmacy premises are in the area specified in the announcement, during the period when, in the circumstances specified in the announcement, eligible patients need to stay away from P’s pharmacy, P must ascertain from—

(a) an eligible patient—

 (i) who has contacted P about the home delivery of prescription items, or

 (ii) who is a person whom P considered, on the basis of the nature of an item on a prescription form, might be an eligible person and accordingly, in the ordinary exercise of professional skill and judgement, made the appropriate checks and determined that they were; or

(b) a person who may make an application for pharmaceutical services on behalf of that eligible patient (a “duly authorised person”) who has contacted P about the home delivery of prescription items,

whether or not the item could be supplied by a duly authorised person, and if it could, then supplying the item via a duly authorised person is the home delivery option which P must provide.

(3) Where paragraph (2) does not apply, if P’s pharmacy premises are in the area specified in the announcement, during the period when, in the circumstances specified in the announcement, eligible patients need to stay away from P’s pharmacy, the home delivery option that P must provide must comprise—

(a) P delivering the item to the eligible patient’s home or to an alternative address agreed with the patient or a duly authorised person (for example, a care home where the patient is temporarily residing);

(b) P arranging for an item dispensed by P to be delivered by another pharmacist to the eligible patient’s home or to an alternative address agreed with the patient or a duly authorised person; or

(c) if P is unable to deliver the item or arrange for its delivery by another pharmacist, P arranging for the dispensing or supply of the item by another pharmacist who would be able to deliver the dispensed item to the eligible patient’s home or to an alternative address agreed with the patient or a duly authorised person.

(4) Paragraph (1) does not apply where the eligible patient or a duly authorised person is already at P’s pharmacy premises for the purposes of receiving dispensing services.

(5) Notwithstanding the foregoing provisions of this Part, in any case of a supply in accordance with a home delivery option, if but for this sub-paragraph that supply would need to be made with reasonable promptness, P may instead, in the exercise of professional skill and judgment, make the supply within a reasonable timescale.

(6) Where arrangements are in place which enable a pharmacist to make a delivery as mentioned in sub-paragraph 3(a) or (b) as part of a directed service, the pharmacist must deliver the item as part of that directed service.

(7) This paragraph does not apply to a pharmacist in respect of distance selling premises..

* 1. After paragraph 15A([[9]](#footnote-9)) (supply in accordance with a SSP) insert—

Home delivery service while a disease is or in anticipation of a disease being imminently pandemic etc.

**15B.**—(1) Before dispensing any item on a prescription form or supplying it in accordance with a serious shortage protocol, a dispensing doctor (D) must provide a home delivery option to eligible patients in respect of the item where, as a consequence of a disease being or in anticipation of a disease being imminently—

(a) pandemic; and

(b) a serious risk or potentially a serious risk to human health,

the Board with the agreement of the Department has made an announcement to the effect that, in order to assist in the management of the serious risk or potentially serious risk to human health, eligible patients are advised to stay away from listed dispensing premises in the area specified, in the circumstances specified and for the duration of the period specified in the announcement.

(2) If D’s listed dispensing premises are in the area specified in the announcement, during the period when, in the circumstances specified in the announcement, eligible patients need to stay away from D’s premises, D must ascertain from—

(a) an eligible patient—

 (i) who has contacted D about the home delivery of prescription items, or

 (ii) who is a person whom D considered, on the basis of the nature of an item on a prescription form, might be an eligible person and accordingly, in the ordinary exercise of professional skill and judgment, made the appropriate checks and determined that they were; or

(b) a person who may make an application for pharmaceutical services on behalf of that eligible patient (a “duly authorised person”) who has contacted D about the home delivery of prescription items,

whether or not the item could be supplied by a duly authorised person, and if it could, then supplying the item via a duly authorised person is the home delivery option which D must provide.

(3) Where paragraph (2) does not apply, if D’s listed dispensing premises are in the area specified in the announcement, during the period when, in the circumstances specified in the announcement, eligible patients need to stay away from D’s premises, the home delivery option that P must provide must comprise—

(a) D delivering the item to the eligible patient’s home or to an alternative address agreed with the patient or a duly authorised person (for example, a care home where the patient is temporarily residing);

(b) D arranging for an item dispensed by D to be delivered by another dispensing doctor, or by a pharmacist, to the eligible patient’s home or to an alternative address agreed with the patient or a duly authorised person; or

(c) if D is unable to deliver the item or arrange for its delivery by another dispensing doctor, or by a pharmacist, D arranging for the dispensing or supply of the item by another dispensing doctor, or by a pharmacist, who would be able to deliver the dispensed item to the eligible patient’s home or to an alternative address agreed with the patient or a duly authorised person.

(4) Paragraph (1) does not apply where the eligible patient or a duly authorised person is already at D’s listed dispensing premises for the purposes of receiving dispensing services.

(5) Notwithstanding the foregoing provisions of this Schedule, in any case of a supply in accordance with a home delivery option, if but for this sub-paragraph that supply would need to be made with reasonable promptness, D may instead, in the exercise of professional skill and judgment, make the supply within a reasonable timescale..

Sealed with the Official Seal of the Department of Health on \*\*\*

(L.S.)

 Name

 A senior officer of the Department of Health

Sealed with the Official Seal of the Department of Finance on \*\*\*

(L.S.)

 Name

 A senior officer of the Department of Finance

EXPLANATORY NOTE

(This note is not part of the Regulations)

These Regulations amend the Pharmaceutical Services Regulations (Northern Ireland) 1997 (“the Pharmaceutical Regulations”) which govern the arrangements for the provision of pharmaceutical services under the Health and Personal Social Services (Northern Ireland) Order 1972 (“the 1972 Order”).

Various measures are put in place to deal with matters arising as consequence of a disease being, or in anticipation of a disease being imminently, pandemic and a serious risk or potentially a serious risk to human health – essentially in order to assist in the management of the serious risk or potentially serious risk to human health.

The Regional Health and Social Care Board, “the Board”, which commissions pharmaceutical services in Northern Ireland, may need to ask chemists to prioritise delivery of particular pharmaceutical services. Where the Board has made an announcement to the effect that specified terms of service of chemists are suspended in specified circumstances for a limited period, during that limited period the suspended terms will not form part of the arrangements to provide pharmaceutical services which chemists have with the Board. (Regulation 3). Similarly, if the Board has made an announcement to the effect that a specified term of service need not be complied with in specified circumstances for a limited period, enforcement action cannot be taken against chemists in relation to noncompliance with that term in that period. (Regulation 4).

The Board may also need to vary the opening hours of pharmacy premises – either increasing them or decreasing them. The Board may also need to require pharmacies and dispensing doctor surgeries to provide a home delivery option for prescription items, in circumstances where certain classes of patients are advised to stay away from pharmacies and dispensing doctor surgeries, and so will need to obtain their prescription items in other ways. (Regulation 5 (2), (3) and (4).

There are also ancillary provisions dealing with amendment and withdrawal of advice and announcements.

Annex 1

**LIST OF CONSULTEES**

The Health and Social Care Board

The Pharmaceutical Society of Northern Ireland

Community Pharmacy NI

British Medical Association

Royal College of General Practitioners

The Patient and Client Council

Ulster Chemists’ Association

National Pharmacy Association

Pharmacists’ Defence Association

Pharmacy Forum NI

1. () Formerly the Department of Health, Social Services and Public Safety; see 2016 c. 5 (N.I.), section 1(5) [↑](#footnote-ref-1)
2. () Formerly the Department of Finance and Personnel; see 2016 c. 5 (N.I.), section 1(4) [↑](#footnote-ref-2)
3. () S.I. 1972/1265 (N.I. 14); the relevant amending instruments are S.I. 1978/1907 (N.I. 26) Article 14; S.I. 1986/2023 (N.I. 20) Articles 5(1) and (2); S.I. 1986/2229 (N.I. 24); S.I. 1988/2249 (N.I. 24) Article 7; S.I. 1991/194 (N.I. 1) Articles 3(1) and (2), 34 and Part II of Schedule 5; S.I. 1992/2671 (N.I. 18) Article 3; S.I. 1997/1177 (N.I. 7) Article 29; 2001 c. 3 (N.I.) section 48 and 2008 c. 2 (N.I.) section 10 [↑](#footnote-ref-3)
4. () S.R. 1997 No. 381; relevant amending instruments are S.R. 1998 No. 95, S.R. 1999 Nos. 100, 254 and 405, S.R. 2001 No. 222, S.R. 2002 Nos. 92 and 397, S.R. 2003 No. 447, S.R. 2005 No. 231, S.R. 2009 Nos. 191 and 320, S.R. 2010 No. 72, S.R. 2014 No. 170, S.R. 2016 No. 104 and S.R. 2019 No. 186 [↑](#footnote-ref-4)
5. () S.I. 1972/1265 (N.I. 14) [↑](#footnote-ref-5)
6. () Regulation 3 was substituted by S.R. 2001 No. 222, reg 3 [↑](#footnote-ref-6)
7. () Paragraph 4A was inserted into Schedule 2 by S.R. 2009 No. 320, reg 6 [↑](#footnote-ref-7)
8. () Paragraph 5B was inserted into Schedule 2 by S.R. 2019 No. 186, reg 4(2) [↑](#footnote-ref-8)
9. () Paragraph 15A was inserted into Schedule 2 by S.R. 2019 No. 186, reg 4(3) [↑](#footnote-ref-9)